Hiranda Dodanwala, MD
Rheumatology · Hershey, PANPI 1104180496
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 52 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Amgen at 27.3% of the total. Reporting peaked in 2019 at $667 and has fallen 97.6% since, to $16 in 2024. That places this record below the midpoint for rheumatology clinicians in PA, where the typical reported total is $1,951.
Across 52 payments — averaging $16.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$239
- AbbVie$196
- UCB, Inc.$66
- Bristol Myers Squibb$63
- Novartis$51
- Sobi, Inc$40
- plus $221 from 10 others
What the payments were for
- Food & beverage$875100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 14 | $239 |
| AbbVie | 12 | $196 |
| UCB, Inc. | 4 | $66 |
| Bristol Myers Squibb | 3 | $63 |
| Novartis | 3 | $51 |
| Sobi, Inc | 2 | $40 |
| Lilly USA, LLC | 2 | $35 |
| Boehringer Ingelheim | 2 | $31 |
| Pfizer | 2 | $30 |
| Actelion Pharmaceuticals US, Inc. | 1 | $27 |
| E.r. Squibb & Sons, L.L.C. | 2 | $26 |
| GSK | 1 | $16 |
| Radius Health, Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Genentech USA, Inc. | 1 | $13 |
| Gilead | 1 | $11 |
How this compares
$875 in reported general payments places this provider in the 40th percentile of 351 rheumatology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 20 | $135,412 |
| MethotrexateMethotrexate Sodium | 30 | $930 |
| Hydroxychloroquine Sulfate | 23 | $873 |
| Sulfasalazine | 15 | $500 |
| Methylprednisolone | 25 | $178 |
| Prednisone | 25 | $156 |
| Allopurinol | 13 | $35 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Hershey
- Alan EpsteinPhiladelphia$1.2M
- Lawrence LeventhalHuntingdon Valley$1.1M
- Alan KivitzDuncansville$936K
- Paula HerringNewtown Square$920K
- Rohit AggarwalPittsburgh$810K
- Frederick MurphyDuncansville$494K
- Peter MerkelRadnor$479K
- Martin BergmanRidley Park$458K
- Alexis Ogdie-BeattyPhiladelphia$433K
- Ellen FieldBethlehem$418K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.